129 related articles for article (PubMed ID: 3323260)
21. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial.
Abrams J; Allen J; Allin D; Anderson J; Anderson S; Blanski L; Chadda K; DiBianco R; Favrot L; Gonzalez J
Am Heart J; 1985 Nov; 110(5):913-22. PubMed ID: 3904379
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis.
Regårdh CG; Jordö L; Ervik M; Lundborg P; Olsson R; Rönn O
Clin Pharmacokinet; 1981; 6(5):375-88. PubMed ID: 7333059
[TBL] [Abstract][Full Text] [Related]
23. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.
Mooss AN; Hilleman DE; Mohiuddin SM; Hunter CB
Ann Pharmacother; 1994 Jun; 28(6):701-3. PubMed ID: 7919552
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of esmolol in unstable angina pectoris. European Esmolol Study Group.
Hohnloser SH; Meinertz T; Klingenheben T; Sydow B; Just H
Am J Cardiol; 1991 Jun; 67(16):1319-23. PubMed ID: 1675036
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolus.
Sintetos AL; Hulse J; Pritchett EL
Clin Pharmacol Ther; 1987 Jan; 41(1):112-7. PubMed ID: 2879662
[TBL] [Abstract][Full Text] [Related]
26. Esmolol, the first ultra-short-acting intravenous beta blocker for use in critically ill patients.
Blanski L; Lutz J; Laddu A
Heart Lung; 1988 Jan; 17(1):80-9. PubMed ID: 3276651
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of esmolol and fentanyl in controlling increases in heart rate and blood pressure during endotracheal intubation.
Gaubatz CL; Wehner RJ
AANA J; 1991 Feb; 59(1):91-6. PubMed ID: 1672049
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular and antiarrhythmic effects of esmolol in children.
Trippel DL; Wiest DB; Gillette PC
J Pediatr; 1991 Jul; 119(1 Pt 1):142-7. PubMed ID: 1676729
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of esmolol for unstable angina pectoris.
Wallis DE; Pope C; Littman WJ; Scanlon PJ
Am J Cardiol; 1988 Nov; 62(16):1033-7. PubMed ID: 2903659
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias.
Byrd RC; Sung RJ; Marks J; Parmley WW
J Am Coll Cardiol; 1984 Feb; 3(2 Pt 1):394-9. PubMed ID: 6141193
[TBL] [Abstract][Full Text] [Related]
31. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
Gray RJ; Bateman TM; Czer LS; Conklin CM; Matloff JM
J Am Coll Cardiol; 1985 Jun; 5(6):1451-6. PubMed ID: 2860148
[TBL] [Abstract][Full Text] [Related]
32. A new dosing regimen for esmolol to treat supraventricular tachyarrhythmia in Chinese patients.
Ko WJ; Chu SH
J Am Coll Cardiol; 1994 Feb; 23(2):302-6. PubMed ID: 7905013
[TBL] [Abstract][Full Text] [Related]
33. Intravenous esmolol for the treatment of supraventricular tachyarrhythmia: results of a multicenter, baseline-controlled safety and efficacy study in 160 patients. The Esmolol Research Group.
Am Heart J; 1986 Sep; 112(3):498-505. PubMed ID: 2875641
[TBL] [Abstract][Full Text] [Related]
34. Ultra short-acting intravenous beta-adrenergic blockade as add-on therapy in acute unstable angina.
Barth C; Ojile M; Pearson AC; Labovitz AJ
Am Heart J; 1991 Mar; 121(3 Pt 1):782-8. PubMed ID: 1672051
[TBL] [Abstract][Full Text] [Related]
35. Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade.
Reilly CS; Wood M; Koshakji RP; Wood AJ
Clin Pharmacol Ther; 1985 Nov; 38(5):579-85. PubMed ID: 2865029
[TBL] [Abstract][Full Text] [Related]
36. Pharmacology and pharmacokinetics of esmolol.
Reynolds RD; Gorczynski RJ; Quon CY
J Clin Pharmacol; 1986 Mar; 26(S1):A3-A14. PubMed ID: 2870084
[TBL] [Abstract][Full Text] [Related]
37. Effects of dexmedetomidine and esmolol on systemic hemodynamics and exogenous lactate clearance in early experimental septic shock.
Hernández G; Tapia P; Alegría L; Soto D; Luengo C; Gomez J; Jarufe N; Achurra P; Rebolledo R; Bruhn A; Castro R; Kattan E; Ospina-Tascón G; Bakker J
Crit Care; 2016 Aug; 20(1):234. PubMed ID: 27480413
[TBL] [Abstract][Full Text] [Related]
38. The safety and efficacy of esmolol during myocardial revascularization.
Girard D; Shulman BJ; Thys DM; Mindich BP; Mikula SK; Kaplan JA
Anesthesiology; 1986 Aug; 65(2):157-64. PubMed ID: 3526984
[TBL] [Abstract][Full Text] [Related]
39. Beta 1-adrenoceptor subtype selective antagonism of esmolol and its major metabolite in vitro and in man. Investigations using tricresylphosphate as red blood cell carboxylesterase inhibitor.
Jahn P; Eckrich B; Schneidrowski B; Volz-Zang C; Schulte B; Mutschler E; Palm D
Arzneimittelforschung; 1995 May; 45(5):536-41. PubMed ID: 7612051
[TBL] [Abstract][Full Text] [Related]
40. Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Benfield P; Sorkin EM
Drugs; 1987 Apr; 33(4):392-412. PubMed ID: 2885168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
